Waverley Pharma (TSXV:WAVE) Change In Inventory : C$0.12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Change In Inventory?

Waverley Pharma's change in inventory for the quarter that ended in Mar. 2024 was C$0.00 Mil. It means Waverley Pharma's inventory declined by C$0.00 Mil from Dec. 2023 to Mar. 2024 .

Waverley Pharma's change in inventory for the fiscal year that ended in Dec. 2023 was C$0.06 Mil. It means Waverley Pharma's inventory declined by C$0.06 Mil from Dec. 2022 to Dec. 2023 .

Waverley Pharma's Total Inventories for the quarter that ended in Mar. 2024 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Waverley Pharma's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Waverley Pharma Change In Inventory Historical Data

The historical data trend for Waverley Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Change In Inventory Chart

Waverley Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-0.06

-0.18

-0.07

0.29

0.06

Waverley Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															-0.05	-0.04	0.06	0.09	-

Waverley Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.12 Mil.

Waverley Pharma (TSXV:WAVE) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Waverley Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0.0005	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Waverley Pharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0.0005
	=	0.00

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Waverley Pharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.0005	/	0
	=	N/A

Waverley Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Waverley Pharma (TSXV:WAVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.

Executives

Albert David Friesen

10% Security Holder, Director, Senior Officer